116 related articles for article (PubMed ID: 7599041)
1. TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
Skomedal H; Kristensen G; Helland A; Nesland JM; Kooi S; Børresen AL; Holm R
Br J Cancer; 1995 Jul; 72(1):129-33. PubMed ID: 7599041
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of TP53 alterations in breast carcinoma.
Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
4. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
[TBL] [Abstract][Full Text] [Related]
6. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
Valgardsdottir R; Tryggvadottir L; Steinarsdottir M; Olafsdottir K; Jonasdottir S; Jonasson JG; Ogmundsdottir HM; Eyfjörd JE
APMIS; 1997 Feb; 105(2):121-30. PubMed ID: 9113074
[TBL] [Abstract][Full Text] [Related]
7. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
[TBL] [Abstract][Full Text] [Related]
9. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8.
Hafkamp HC; Speel EJ; Haesevoets A; Bot FJ; Dinjens WN; Ramaekers FC; Hopman AH; Manni JJ
Int J Cancer; 2003 Nov; 107(3):394-400. PubMed ID: 14506739
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
[TBL] [Abstract][Full Text] [Related]
11. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
[TBL] [Abstract][Full Text] [Related]
12. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
Smith-Sørensen B; Gebhardt MC; Kloen P; McIntyre J; Aguilar F; Cerutti P; Børresen AL
Hum Mutat; 1993; 2(4):274-85. PubMed ID: 8401536
[TBL] [Abstract][Full Text] [Related]
13. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue.
Berner A; Geitvik G; Karlsen F; Fosså SD; Nesland JM; Børresen AL
J Pathol; 1995 Jul; 176(3):299-308. PubMed ID: 7674092
[TBL] [Abstract][Full Text] [Related]
15. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 protein related to the presence of human papillomavirus (HPV) DNA in genital carcinomas and precancer lesions.
Tervahauta AI; Syrjänen SM; Väyrynen M; Saastamoinen J; Syrjänen KJ
Anticancer Res; 1993; 13(4):1107-11. PubMed ID: 8394670
[TBL] [Abstract][Full Text] [Related]
17. Analysis of p53 status in tonsillar carcinomas associated with human papillomavirus.
Snijders PJ; Steenbergen RD; Top B; Scott SD; Meijer CJ; Walboomers JM
J Gen Virol; 1994 Oct; 75 ( Pt 10)():2769-75. PubMed ID: 7931165
[TBL] [Abstract][Full Text] [Related]
18. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma.
Lavarino C; Corletto V; Mezzelani A; Della Torre G; Bartoli C; Riva C; Pierotti MA; Rilke F; Pilotti S
Br J Cancer; 1998; 77(1):125-30. PubMed ID: 9459157
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
Andersen TI; Børresen AL
Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
[TBL] [Abstract][Full Text] [Related]
20. Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis.
Chang F; Syrjänen S; Tervahauta A; Kurvinen K; Wang L; Syrjänen K
Br J Cancer; 1994 Aug; 70(2):346-51. PubMed ID: 8054284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
